ATE539764T1 - Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen - Google Patents
Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungenInfo
- Publication number
- ATE539764T1 ATE539764T1 AT08786266T AT08786266T ATE539764T1 AT E539764 T1 ATE539764 T1 AT E539764T1 AT 08786266 T AT08786266 T AT 08786266T AT 08786266 T AT08786266 T AT 08786266T AT E539764 T1 ATE539764 T1 AT E539764T1
- Authority
- AT
- Austria
- Prior art keywords
- antithrombins
- mutant
- treat
- prevent clotting
- clotting diseases
- Prior art date
Links
- 206010053567 Coagulopathies Diseases 0.000 title abstract 2
- 239000004019 antithrombin Substances 0.000 title abstract 2
- 230000035602 clotting Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 230000009852 coagulant defect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014508 negative regulation of coagulation Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290913 | 2007-07-20 | ||
| PCT/EP2008/059486 WO2009013251A1 (en) | 2007-07-20 | 2008-07-18 | Use of mutated antithrombins for treating or preventing coagulation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE539764T1 true ATE539764T1 (de) | 2012-01-15 |
Family
ID=39111552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08786266T ATE539764T1 (de) | 2007-07-20 | 2008-07-18 | Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8741844B2 (de) |
| EP (1) | EP2175877B1 (de) |
| JP (1) | JP2010533684A (de) |
| AT (1) | ATE539764T1 (de) |
| CA (1) | CA2694047C (de) |
| DK (1) | DK2175877T3 (de) |
| WO (1) | WO2009013251A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010081878A1 (en) * | 2009-01-16 | 2010-07-22 | Universite Paris-Sud Xi | Mutated antithrombins, a process for preparing the same and their use as drugs |
| US20140356377A1 (en) * | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| HK1215261A1 (zh) | 2013-03-14 | 2016-08-19 | Bayer Healthcare Llc | 針對與肝素複合的抗凝血酶β的單克隆抗體 |
| GB201322091D0 (en) | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| EP3212794B1 (de) | 2014-10-30 | 2021-04-07 | Genzyme Corporation | Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon |
| ES3041380T3 (en) | 2015-12-07 | 2025-11-11 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| ES2992695B2 (es) * | 2023-06-15 | 2025-07-23 | Fundacion Para La Formacion E Investig Sanitarias De La Region De Murcia [Ffiis | Antidoto |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3901917A1 (de) * | 1989-01-24 | 1990-07-26 | Behringwerke Ag | Mutanten von humanem antithrombin iii |
| JP3479539B2 (ja) * | 1992-04-10 | 2003-12-15 | エーザイ株式会社 | ヒトアンチトロンビンｉｉｉ変異体 |
| JPH0971600A (ja) * | 1995-09-06 | 1997-03-18 | Eisai Co Ltd | ヒトアンチトロンビンｉｉｉ 変異体 |
| AU782069B2 (en) * | 1999-05-13 | 2005-06-30 | Gtc Biotherapeutics, Inc. | Transgenically produced antithrombin III and mutants thereof |
| WO2005009361A2 (en) * | 2003-07-17 | 2005-02-03 | Smithkline Beecham Corporation | Method of treating hit patients with argatroban |
-
2008
- 2008-07-18 US US12/669,855 patent/US8741844B2/en not_active Expired - Fee Related
- 2008-07-18 WO PCT/EP2008/059486 patent/WO2009013251A1/en not_active Ceased
- 2008-07-18 DK DK08786266.0T patent/DK2175877T3/da active
- 2008-07-18 JP JP2010516522A patent/JP2010533684A/ja active Pending
- 2008-07-18 EP EP08786266A patent/EP2175877B1/de not_active Not-in-force
- 2008-07-18 AT AT08786266T patent/ATE539764T1/de active
- 2008-07-18 CA CA2694047A patent/CA2694047C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010533684A (ja) | 2010-10-28 |
| DK2175877T3 (da) | 2012-04-16 |
| EP2175877B1 (de) | 2012-01-04 |
| US8741844B2 (en) | 2014-06-03 |
| CA2694047A1 (en) | 2009-01-29 |
| WO2009013251A1 (en) | 2009-01-29 |
| US20100298224A1 (en) | 2010-11-25 |
| CA2694047C (en) | 2018-01-30 |
| EP2175877A1 (de) | 2010-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE539764T1 (de) | Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| MX2010004074A (es) | Combinacion 059. | |
| TR201820051T4 (tr) | Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması | |
| EP3623470A3 (de) | Faktor-ix-varianten mit gerinnungsaktivität in abwesenheit ihres cofaktors und deren verwendung zur behandlung von blutungsstörungen | |
| ATE516353T1 (de) | Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs | |
| WO2009045356A8 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
| MX2010003095A (es) | Antidotos para inhibidores del factor xa y metodos para usar los mismos. | |
| UA98125C2 (ru) | Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний | |
| EA201100440A1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| EP2331192A4 (de) | Mikroelektrodenstimulation zur behandlung von epilepsie und anderen neurologischen erkrankungen | |
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| ATE453642T1 (de) | Substituierte phenylaminopyrimidine | |
| CY1113580T1 (el) | Υποκατεστημενα (οξαζολιδινον-5-υλ-μεθυλ)-2-θειοφαινο-καρβοξαμιδια και χρηση αυτων στο πεδιο της πηξης του αιματος | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| PH12012502070A1 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
| DE502007004579D1 (de) | Aryl-substituierte heterozyklen und ihre verwendung | |
| MX2010005545A (es) | Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca. | |
| ZA200908583B (en) | Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation | |
| WO2022235551A3 (en) | Fc-fusion protein therapeutic for the treatment of pancreatitis | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit |